Cardiovascular Medicines · LP-055
Nifedipine Tablets
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-055Cardiovascular Medicines
- Generic identity
- NifedipineTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-055
- Generic identity
- Nifedipine
- Presentation
- Tablet
- Catalogue strength
- 10 mg immediate-release; 20 mg modified-release; 30 mg extended-release
- Catalogue pack
- Blister 10 x 10 tablets
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: Nifedipine.
- Dosage form: tablet.
- Catalogue strength / concentration: 10 mg immediate-release; 20 mg modified-release; 30 mg extended-release.
- Catalogue pack: Blister 10 x 10 tablets.
- Catalogue category: Cardiovascular Medicines.
Layer 02 · Unresolved product-specific fields
- Exact finished-product composition, excipients and manufacturing specification.
- Exact pharmaceutical technology and controlled release/dissolution specification for each IR/MR/ER variant, plus controlled SKU mapping for the common blister description.
- Approved indication, patient eligibility, dose/administration and contraindication wording for the exact product/jurisdiction.
- Storage conditions, shelf life, registration/market status, manufacturing route and current supply status.
Identity note
The external extended-release label confirms that release technology is a product-defining characteristic. It does not establish LP-055 equivalence or permit conversion among its three catalogue variants.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 10 mg immediate-release | Tablet | Immediate release | Catalogue lists blister 10 x 10 tablets; strength-specific controlled SKU evidence not supplied | Release descriptor is part of the controlled catalogue value. Do not infer dose conversion, interchangeability or equivalence across IR/MR/ER variants. |
| B | 20 mg modified-release | Tablet | Modified release | Catalogue lists blister 10 x 10 tablets; strength-specific controlled SKU evidence not supplied | Release descriptor is part of the controlled catalogue value. Do not infer dose conversion, interchangeability or equivalence across IR/MR/ER variants. |
| C | 30 mg extended-release | Tablet | Extended release | Catalogue lists blister 10 x 10 tablets; strength-specific controlled SKU evidence not supplied | Release descriptor is part of the controlled catalogue value. Do not infer dose conversion, interchangeability or equivalence across IR/MR/ER variants. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Nifedipine is a calcium-channel blocker used in selected vascular and cardiovascular conditions. Immediate-release, modified-release and extended-release products can behave very differently and must be distinguished explicitly. A shared ingredient name or similar milligram value does not establish interchangeability. This educational page does not establish Luang Pharma approved indications, validate a release system or recommend immediate-release treatment for an episode of high blood pressure.
Clinical context and therapeutic role
The clinician selects the precise formulation according to the diagnosis and the authorized product information. Ongoing management of hypertension or angina is different from assessment of an acute emergency. Release characteristics, other cardiovascular medicines and liver disease can influence selection. A substitution must preserve the intended formulation and instructions, not simply the ingredient. Severe headache with neurologic symptoms, acute chest pain or major breathlessness requires urgent clinical assessment.
Selected safety context
Headache, flushing, ankle swelling, dizziness and palpitations can occur. Excessive hypotension or worsening chest pain needs prompt review. Crushing or otherwise altering some modified-release products can change drug delivery and create risk. Interacting medicines and grapefruit may affect exposure, so the exact leaflet should be checked. A tablet should not be used for rapid unsupervised blood-pressure lowering. Fainting, severe chest pain or signs of a serious allergic reaction requires urgent care.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue describes a tablet presentation. The exact salt, coating, score line and release characteristics need confirmation from the authorized product information. A milligram strength identifies ingredient quantity; it does not establish whether a tablet may be split, crushed or exchanged for another formulation.
Keep the product in its labeled packaging so the batch, expiry and instructions remain identifiable. Follow the actual label for storage conditions and disposal. Do not use a damaged or unidentified tablet, and keep all medicines securely out of children’s reach.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A qualified clinician should review the cardiovascular indication, blood pressure or pulse where relevant, organ function and interacting medicines. Monitoring and treatment changes must be linked to the individual care plan and the authorized product information.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification and quantitative composition for each exact presentation.
Approved/controlled label or leaflet for the intended jurisdiction.
Strength/form-to-pack SKU matrix and controlled packaging artwork where more than one variant is listed.
Registration/market-status and manufacturing-site evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07c checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| NHS: NifedipineArchived source classification: Public-health medicine reference | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
| DailyMed: Nifedipine extended-release tablet exampleArchived source classification: US official drug label example | Source revision recorded: Label updated 16 June 2026; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-055.
Professional enquiries
Request product-specific evidence for LP-055.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.